Results 71 to 80 of about 6,882 (175)

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, Volume 209, Issue 4, Page 1818-1827, October 2026.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source

Eltrombopag – a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations

, 2010
Lucy Cook, Nichola CooperDepartment of Haematology, Imperial Health Care NHS Trust, Hammersmith Hospital, London, UKAbstract: Eltrombopag is one of a number of novel agents recently developed for use in the treatment of patients with immune ...
Nichola Cooper, Lucy Cook
core  

Efficacy and safety of eltrombopag in the treatment of severe chronic immune thrombocytopenia in children of China: A single-center observational study

International Journal of Immunopathology and Pharmacology, 2019
The treatment of severe chronic immune thrombocytopenia (SCITP) in pediatric patients is challenging. We evaluated the clinical efficacy and safety of eltrombopag in children with SCITP in China. This observational study was carried out at the Hematology
Xiaoling Cheng, Kuo Yan, Jingyao Ma, Zhenping Chen, Libo Zhao, Xiaoling Wang, Runhui Wu   +6 more
doaj   +1 more source

A case of immune thrombocytopenia due to miliary tuberculosis effectively treated with eltrombopag

Respiratory Medicine Case Reports, 2020
An 80-year-old woman was diagnosed with miliary tuberculosis. Laboratory findings showed marked thrombocytopenia (3000/μl). Immune thrombocytopenia (ITP) was diagnosed because platelet transfusion was ineffective, and bone marrow puncture demonstrated a ...
Hiroshi Wada, Takuto Sakashita
doaj   +1 more source

Predictors for eltrombopag response in patients with hepatitis C virus-associated thrombocytopenia

, 2019
Tamer A Elbedewy,1 Mohamed A Elsebaey,1 Samah A Elshweikh,1 Heba Elashry,2 Sherief Abd-Elsalam2 1Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Tropical Medicine Department, Faculty of Medicine, Tanta University ...
Elbedewy TA, Elashry H, Elshweikh SA, Abd-Elsalam S, Elsebaey MA   +4 more
core  

The safety profile of eltrombopag, a novel oral platelet growth factor, in thrombocytopenic patients and healthy subjects

, 2006
Background: Eltrombopag (SB-497115) is an oral, non-peptide, small molecule, thrombopoietin receptor agonist being tested as a potential treatment for thrombocytopenia.
Uhl, J., Provan, D., Goodison, S., Rafi, R., Hassani, H., Saleh, Mansoor, Hamilton, J. M., Jenkins, J., Stone, N., Mayer, B.   +9 more
core   +1 more source

Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists [PDF]

, 2016
Eltrombopag is a thrombopoietin mimetic used for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia, hepatitis C patients undergoing antiviral therapy, and thrombocytopenia secondary to aplastic anemia that is refractory ...
Martin, Sabrina, Kazemi, Tiana, Worswick, Scott, Kazemi, Tiana ; Martin, Sabrina ; Worswick, Scott, Sabrina Martin, Tiana Kazemi, Scott Worswick   +6 more
core   +1 more source

Efficacy and Safety of Eltrombopag 25 Mg for the Management of Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumours: A Retrospective Comparative Study

National Board of Examinations Journal of Medical Sciences
Background: Chemotherapy-induced thrombocytopenia (CIT) can compromise chemotherapy delivery in patients with solid tumours. This study evaluated the efficacy and safety of eltrombopag 25 mg compared with standard supportive care.
Lingeshwaran S, K. B. Akila, Nithiya Piriya C R, M. Prabagar   +3 more
doaj   +1 more source

Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation

Therapeutic Advances in Hematology, 2020
Background: Patients with post-transplant cytopenias due to poor graft function or primary engraftment failure show poor prognosis with a high mortality rate mainly because of graft versus host disease (GVHD), infection and/or bleeding. Treatment options
Semra Aydin, Chiara Dellacasa, Sara Manetta, Luisa Giaccone, Laura Godio, Giorgia Iovino, Benedetto Bruno, Alessandro Busca   +7 more
doaj   +1 more source

Thromboembolic events observed in eltrombopag clinical trials in chronic immune thrombocytopenic purpura.

, 2009
BACKGROUND: Eltrombopag (PROMACTA®; GlaxoSmithKline, Collegeville, PA, USA), an oral, small molecule, thrombopoietin receptor agonist, was recently approved in the United States for the treatment of patients with chronic immune thrombocytopenic purpura ...
Cheng, Gregory, Saleh, Mansoor, Bussel, James, Vasey, Sandra, Aivado, Manuel, Brainsky, Andres   +5 more
core   +1 more source